Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Lupus/Nephritis -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (36)	11/15/2001 5:57:26 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 95

Really interesting. >>The analyses, he said, revealed that dendritic cells are produced very efficiently when blood cells from normal donors were cultured with the serum from lupus patients. Then the researchers identified alpha interferon as the primary substance responsible for this effect, he said. The researchers found that the young patients’ dendritic cells capture blood-carried debris of normal cells that have died, Pascual said. Dead-cell components, she added, normally are removed by scavenger cells, and the immune system never encounters that waste. But this is not true in lupus patients, she said. << Thanks! Now, how many ways are there to cause expression of ifn-a? And haven't Dr.s been prescribing ifn-a forever without causing lupus?